Copy to clipboard 
Xtant Medical completed its previously announced sale of certain non-core Coflex spinal implant assets and all OUS entities of Paradigm Spine to Companion Spine and its affiliates.
Paradigm Spine will retain its name and branding and maintain its office in Wurmlingen, Germany. Anthony G. Viscogliosi will lead the combined company as Executive Chairman and Chief Executive Officer, and Enrico Sangiorgio will be Executive Vice President International of Paradigm Spine and General Manager of Companion Spine outside of the U.S. William Pfost will continue in his role as Chief Sales Officer of Companion Spine, focused on the U.S. markets.
Companion Spine’s combined portfolio of products and uses include: Coflex when a decompression is required for LSS or CoFix when a larger decompression is needed and there exists more instability for LSS, LISA Lumbar Implant for Stiffness Augmentation to address a decompression with significant instability requiring greater stabilization, or the HPS 2.0 Hybrid Performance System when there is significant instability but a desire to preserve adjacent segments. In the cervical anatomy, the DCI Dynamic Cervical Implant is designed as a Coflex concept applied in an anterior interbody fashion for maintenance of motion. Lastly, Companion Spine’s DIAM Spinal Stabilization System product is designed for use in DDD patients.
Sean Browne, President and CEO of Xtant Medical, stated, “The sale of these businesses to Companion Spine represents a significant step forward for Xtant as we enhance our focus on our core biologics business, driving innovation for surgeons and patients, and delivering sustained improvements in our financial performance. Importantly, we expect that the net proceeds from this transaction, together with our anticipated cash flows generated from operations, will enable us to continue operating without the need for additional external capital. We are immensely proud to have reached this inflection point.”
The operating contributions of these assets and entities are included in Xtant’s results through their December 1, 2025 date of sale.
Xtant Medical completed its previously announced sale of certain non-core Coflex spinal implant assets and all OUS entities of Paradigm Spine to Companion Spine and its affiliates.
Paradigm Spine will retain its name and branding and maintain its office in Wurmlingen, Germany. Anthony G. Viscogliosi will lead the combined company as...
Xtant Medical completed its previously announced sale of certain non-core Coflex spinal implant assets and all OUS entities of Paradigm Spine to Companion Spine and its affiliates.
Paradigm Spine will retain its name and branding and maintain its office in Wurmlingen, Germany. Anthony G. Viscogliosi will lead the combined company as Executive Chairman and Chief Executive Officer, and Enrico Sangiorgio will be Executive Vice President International of Paradigm Spine and General Manager of Companion Spine outside of the U.S. William Pfost will continue in his role as Chief Sales Officer of Companion Spine, focused on the U.S. markets.
Companion Spine’s combined portfolio of products and uses include: Coflex when a decompression is required for LSS or CoFix when a larger decompression is needed and there exists more instability for LSS, LISA Lumbar Implant for Stiffness Augmentation to address a decompression with significant instability requiring greater stabilization, or the HPS 2.0 Hybrid Performance System when there is significant instability but a desire to preserve adjacent segments. In the cervical anatomy, the DCI Dynamic Cervical Implant is designed as a Coflex concept applied in an anterior interbody fashion for maintenance of motion. Lastly, Companion Spine’s DIAM Spinal Stabilization System product is designed for use in DDD patients.
Sean Browne, President and CEO of Xtant Medical, stated, “The sale of these businesses to Companion Spine represents a significant step forward for Xtant as we enhance our focus on our core biologics business, driving innovation for surgeons and patients, and delivering sustained improvements in our financial performance. Importantly, we expect that the net proceeds from this transaction, together with our anticipated cash flows generated from operations, will enable us to continue operating without the need for additional external capital. We are immensely proud to have reached this inflection point.”
The operating contributions of these assets and entities are included in Xtant’s results through their December 1, 2025 date of sale.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
